Antidiabetic Activity of a Ghanaian Herbal Product, DBT-57A: An Observational Study

IntroductionThe rising global burden of diabetes mellitus has led to growing interest in herbal therapies as alternative or complementary treatments. In many low-resource settings, herbal medicines remain a cornerstone of diabetes management. DBT-57A, a Ghanaian polyherbal formulation, has been used in routine community health practice for over three decades without formal scientific evaluation. This study assessed its real-world clinical effectiveness and safety among patients with type 2 diabetes mellitus (T2DM). MethodsA 28-day prospective non-randomized observational study was conducted involving 25 adults with clinically diagnosed T2DM who were already receiving DBT-57A as part of routine care at a Ghanaian health facility. Fasting blood sugar (FBS) levels were recorded at baseline, Day 14, and Day 28. Diabetes-related symptoms (polyuria, nocturia, weight loss) and any adverse events were documented through patient interviews. Statistical analysis was performed using a paired t-test to compare FBS levels at baseline and at Days 14 and 28. Ethical approval was obtained from the Committee on Human Research, Publications and Ethics at KNUST/Komfo Anokye Teaching Hospital. ResultsMean FBS levels decreased significantly by 49.8%, from 18.34 {+/-} 6.54 mmol/L at baseline to 9.19 {+/-} 3.76 mmol/L on Day 28 (p < 0.05). Symptomatic relief was reported by 95.2% of participants. No serious adverse events occurred. ConclusionDBT-57A showed promising glucose-lowering effects and symptom improvement in this observational cohort. These findings support further investigation through randomized controlled trials to confirm its efficacy, ensure safety, and explore its role in integrative diabetes care in low-resource settings.